Status:
COMPLETED
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Dyskinesias
Drug-induced
Eligibility:
All Genders
30-85 years
Phase:
PHASE2
Brief Summary
This study will assess the safety, tolerability and efficacy of AQW051 in treating moderate to severe L-dopa induced dyskinesias (movement disorders) in patients with Parkinson's disease.
Eligibility Criteria
Inclusion
- Patients with Parkinson's disease
- Patients with dyskinesias for at least 3 months
- Patients with moderate to severe dyskinesias
- Patients on L-dopa treatment for at least 3 years
Exclusion
- Patients with atypical Parkinson's disease
- Patients who have had prior surgery for Parkinson's disease
- Patients who are cognitively impaired, have psychosis, have confusional states or hallucinate
- Patients who received neuroleptics or anti-psychotics within 2 months
- Women of child-bearing potential
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
September 15 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 21 2013
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT01474421
Start Date
September 15 2011
End Date
February 21 2013
Last Update
December 24 2020
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Sacramento, California, United States, 95817
2
Novartis Investigative Site
Manhasset, New York, United States, 11030
3
Novartis Investigative Site
Cincinnati, Ohio, United States, 45219
4
Novartis Investigative Site
Cleveland, Ohio, United States, 44195